DRAPER, Utah, March 05, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its fourth quarter and fiscal year end 2024 financial results following the close of regular stock market trading hours on Tuesday, March 19, 2024. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, March 19, 2024, at 4:30 p.m. ET during which management will review the Company’s financial results.
HealthEquity Fourth Quarter and Fiscal Year End 2024 Results Conference Call
| Date: | March 19, 2024 |
| Time: | 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time |
| Dial-In: | 1-833-630-1956 (US and Canada) 1-412-317-1837 (International) |
| Conference ID: | HealthEquity, Inc. call |
| Webcast: | ir.healthequity.com |
A replay of the conference call will be made available on the Company’s website at ir.healthequity.com.
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 15 million benefit accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.
Investor Relations Contact:
Richard Putnam
801-727-1000
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$96.50 |
| Daily Change: | 0.16 0.17 |
| Daily Volume: | 681,820 |
| Market Cap: | US$8.310B |
September 25, 2025 September 02, 2025 March 18, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
